Compare BZ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BZ | ABVX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.6B |
| IPO Year | 2021 | N/A |
| Metric | BZ | ABVX |
|---|---|---|
| Price | $21.07 | $117.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $26.00 | ★ $115.83 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 11-18-2025 | 08-11-2025 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 69.83 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,125,491,208.00 | $6,231,374.00 |
| Revenue This Year | $15.60 | $6.80 |
| Revenue Next Year | $13.18 | N/A |
| P/E Ratio | $27.10 | ★ N/A |
| Revenue Growth | ★ 12.66 | N/A |
| 52 Week Low | $12.85 | $4.77 |
| 52 Week High | $25.26 | $138.49 |
| Indicator | BZ | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 51.08 |
| Support Level | $19.52 | $108.53 |
| Resistance Level | $21.84 | $138.49 |
| Average True Range (ATR) | 0.68 | 7.25 |
| MACD | -0.00 | -1.73 |
| Stochastic Oscillator | 48.04 | 28.51 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.